Dr. Mittendorf is an Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center. At MD Anderson, she focuses both her clinical and laboratory efforts on the study of breast cancer with a specific interest in breast cancer immunotherapy. She is the Principal Investigator on a number of clinical protocols including the phase III PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study, a multicenter phase II trial investigating the efficacy of two additional HER2-derived peptide vaccines and a single institution investigator-initiated phase I trial evaluating combination immunotherapy with vaccines and trastuzumab. Her laboratory work is focused on identifying novel tumor antigens and investigating aspects of the tumor microenvironment that impact the response to vaccination.